Pembrolizumab population PK and exposure
A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.
- Therapeutic
- Pembrolizumab
- Target
- PD-1 / PDCD1
- Disease
- Oncology indications treated with pembrolizumab
Biological model
A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.
Model details
A two-compartment population PK model linking pembrolizumab dosing, body-size effects on disposition, central and peripheral antibody amounts, concentration, and cumulative exposure.
Modeled states
- auc ug day mLug*day/mL
Modeled dynamic state for auc ug day ml.
- central mgmg
Modeled dynamic state for central mg.
- elapsed dayday
Modeled dynamic state for elapsed day.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
Key readouts
- Central pembrolizumab concentrationunknown
Model-derived readout for central pembrolizumab concentration.
- Peripheral pembrolizumab concentrationunknown
Model-derived readout for peripheral pembrolizumab concentration.
- Cumulative pembrolizumab exposureunknown
Model-derived readout for cumulative pembrolizumab exposure.
- auc ug day mLug*day/mL
Model-derived readout for auc ug day ml.
- body weight kgunknown
Model-derived readout for body weight kg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
2 mg/kg every 3 weeks, 77.2 kg
How do dose regimen and body size change pembrolizumab concentration and cumulative exposure? Explore this intervention regimen through Central pembrolizumab concentration, Peripheral pembrolizumab concentration, Cumulative pembrolizumab exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do dose regimen and body size change pembrolizumab concentration and cumulative exposure?
exploratory clearance L day
Model parameter controlling exploratory clearance l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Evaluation of dosing strategy for pembrolizumab for oncology indicationsJournal for ImmunoTherapy of Cancer
